After preliminary in vitro screening of 10 antimicrobial agents against Mycobacterium tuberculosis, the MICs of the 6 most promising agents against 27 clinical isolates were determined by agar dilution. The two quinolone compounds tested (difloxacin and A-56620) were the most active, each inhibiting 50% of the strains at concentrations of 4 ,ug/ml. M. tuberculosis strains previously shown to be resistant to isoniazid, streptomycin, rifampin, or ethambutol were as susceptible to these quinolone compounds as susceptible strains.
The first-line drugs used to treat tuberculosis give satisfactory results with compliant patients and susceptible organisms. Unfortunately, when required, the available second-line drugs are both more toxic and less effective. This latter fact has prompted a continued search for suitable alternative antituberculosis chemotherapeutics. Recent reports of the susceptibility of Mycobacterium tuberculosis to some quinolone compounds (2, 4, 8) and certain cephalosporins (7) are encouraging. The present study expands on these earlier observations by testing the susceptibility of M. tuberculosis to an extended range of modern antimicrobial agents, including several whose activities against this organism have not been previously documented.
The 10 antimicrobial agents tested included two new quinolones, difloxacin (A-56619) and A-56620 (Abbott Laboratories, North Chicago, Ill.); ceforanide and cephapirin (Bristol Laboratories, Ottawa, Ontario, Canada); imipenem (Merck-Frosst Ltd., Pointe-Claire-Dorval, Quebec, Canada); cefotaxime and cefpirome (HR 810) (Roussel Ltd., Montreal, Quebec, Canada); and cefonicid, ceftizoxime, and SK&F 88070 (Smith Kline & French Laboratories, Philadelphia, Pa.).
The test strains of M. tuberculosis comprised 31 recent clinical isolates, 12 of which were susceptible to first-line antituberculosis drugs. Of the remaining 19 strains, 13 were resistant to isoniazid (0.2 ,ug/ml), 6 were resistant to streptomycin (4 ,ug/ml), 4 were resistant to rifampin (2 ,ug/ml), and 6 were resistant to ethambutol (10 ,ug/ml), as determined by using the BACTEC 460 TB instrument (Johnston Laboratories, Inc., Towson, Md.).
All test antimicrobial agents were initially screened at 100 ,ug/ml by using the BACTEC radiometric method (7) . For this preliminary screening, fresh stock solutions (2.2 mg/ml) of the laboratory standard powders were prepared in either distilled water or the manufacturer's recommended buffer, as appropriate, and 0.1 ml of the stock solution was added to a 2.0-ml vial of BACTEC 7H12 Middlebrook TB medium (Johnston Laboratories). To prepare the inoculum, 3-to 5-week-old M. tuberculosis colonies from LowensteinJensen slants were emulsified in diluting fluid containing 0.2% fatty-acid-free albumin and 0.02% polysorbate 80 (pH 6.9). The turbidity of this suspension was adjusted to a * Corresponding author.
McFarland no. 1 standard. Each drug-containing BACTEC vial was inoculated with 0.1 ml of the mycobacterial suspension, giving a final antibiotic test concentration of 100 ,Ig/ml.
The drug-free control vials received a 0.1-ml inoculum of a 1: 100 dilution of the McFarland no. 1 suspension of each strain. The production of CO2 within the vials, as indicated by the growth index, was determined daily until the control vial growth index reached 30 or more. Antimicrobial agents were considered effective at a concentration if the increase in growth index from the previous day was less in the drug vial than in the control.
The MICs were determined by the modified proportion agar dilution method described by Hawkins (6) . Middlebrook and Cohn 7H10 agar (BBL Microbiology Systems, Cockeysville, Md.), supplemented with Middlebrook OADC Enrichment (Difco Laboratories, Detroit, Mich.), was used to prepare quadrant plates with serial twofold dilutions of the various antibiotics. A 100-,I sample of a 10-2 dilution of the McFarland no. 1 suspension of each strain was inoculated to each drug-containing quadrant and a drug-free quadrant. Similarly, an additional drug-free quadrant was inoculated with a l0o' dilution of the same suspension. All plates were then incubated at 35°C in 5% CO2 for 3 weeks. At least 200 CFU on the 10-2 dilution drug-free control quadrant was considered acceptable. The MIC was defined as the lowest antibiotic concentration associated with at least a 99% reduction in the number of visible colonies compared with the drug-free control quadrants.
As shown in Table 1 , 6 of the 10 antimicrobial agents, at concentrations of 100 ,ug/ml, inhibited all strains of M. tuberculosis tested. Of these, the two quinolone compounds, difloxacin and A-56620, were the most effective, each inhibiting the growth of 50% of the strains at 4 ,ug/ml (Table 2 ). M. tuberculosis strains resistant to streptomycin, isoniazid, rifampin, or ethambutol were no more resistant to these quinolone antimicrobial agents than susceptible strains (data not shown).
In conclusion, of the drugs tested, the two quinolone antimicrobial agents were the most active in vitro against M. tuberculosis, irrespective of the susceptibilities of the test strains to standard antituberculosis drugs. The MICs we report are greater than those previously found for other quinolone antimicrobial compounds (4, 8) . Despite this comparatively low in vitro efficacy, several characteristics of one possible. Also, difloxacin may have activity against intracellular M. tuberculosis, since it is rapidly taken up by macrophages (1) and has also been shown to be more effective than other quinolones against intracellular pathogens in animal models (3) . The role of difloxacin as an antituberculosis chemotherapeutic agent must await further evaluation, including clinical trials.
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